Comparison between cigarette smoke-induced emphysema and cigarette smoke extract-induced emphysema

Tobacco Induced Diseases

Jun Cao¹  Hong-Liang Zhang²  Ji-Ru Ye²  Sheng-Dong He²  Yan Chen⁴  Ping Chen²  Zhi-Hui He³ 

[1] Department of Respiratory Medicine, Hunan Provincial People’s Hospital, Changsha 410005, Hunan, China;Department of Respiratory Medicine, The Second Xiangya Hospital, Central-South University, Changsha 410011, Hunan, China;Intensive Care Unit, the Second Xiangya Hospital, Central-South University, Changsha 410011, Hunan, China;Division of Respiratory Disease, Department of Internal Medicine, The Second Xiangya Hospital, Central-South University, Changsha 410011, Hunan, China

关键词: Model;    Emphysema;    Chronic obstructive pulmonary disease (COPD);    Animal;   

Others  :  1159074
DOI  :  10.1186/s12971-015-0033-z

 received in 2014-08-12, accepted in 2015-03-15,  发布年份 2015

【 摘 要 】

Background and objective

Emphysema is the main pathological feature of COPD and also is the focus of the related research. Although several emphysema animal models have been established, exact comparison of findings is seldom. The present study aimed to compare cigarette smoke (CS) exposure-induced emphysema model and intraperitoneal injection of cigarette smoke extract (CSE)-induced emphysema model to evaluate the effectiveness of the two different modeling methods.

Methods

Six-week-old male C57BL/6 J mice were used and randomly divided into two groups: CS exposure and intraperitoneal injection of CSE. Each group was subdivided into two subgroups: control and CS or CSE. Lung function, mean linear intercept (MLI), destructive index (DI), apoptotic index (AI), total and differential cells count in broncholavolar lavage fluid (BALF), SOD and IL-6 concentration in serum were measured.

Results

Compared with their respective controls, lung function was significantly decreased in CS and CSE groups (P < 0.01); MLI, DI, and AI of lung tissue were significantly higher in CS and CSE groups (P < 0.01); total number of leukocytes, the number and percentage of neutrophils (NEUs), and the number of macrophages (MAC) in BALF were significantly higher in CS and CSE groups (P < 0.01); SOD concentration in serum was significantly decreased in CS and CSE groups (P < 0.01); IL-6 concentration in serum was significantly increased in in CS and CSE groups (P < 0.01). There was no significant difference between CS group and CSE group in any of the parameters described above.

Conclusions

Both CS exposure and intraperitoneal injection of CSE could induce emphysema and the effectiveness of the two different modeling methods were equal.

【 授权许可】

   
2015 He et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Fuschillo S, Martucci M, Donner CF, Balzano G: Airway bacterial colonization: the missing link between COPD and cardiovascular events? Respir Med 2012, 106:915-23.
• [2]Miravitlles M: Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med 2011, 105:1118-28.
• [3]Pryor WA, Stone K: Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 1993, 686:12-27.
• [4]Xu CB, Lei Y, Chen Q, Pehrson C, Larsson L, Edvinsson L: Cigarette smoke extracts promote vascular smooth muscle cell proliferation and enhances contractile responses in the vasculature and airway. Basic Clin Pharmacol Toxicol 2010, 107:940-8.
• [5]Zhang H, Chen P, Zeng H, Zhang Y, Peng H, Chen Y, et al.: Protective effect of demethylation treatment on cigarette smoke extract-induced mouse emphysema model. J Pharmacol Sci 2013, 123:159-66.
• [6]He S, He Z, Chen Y, Ye J, Zong D, Zhang Y, et al.: C-Kit/c-Kit ligand interaction of bone marrow endothelial progenitor cells is influenced in acigarette smoke extract-induced emphysema model. Exp Lung Res 2013, 39:258-67.
• [7]World Medical Association; American Physiological Society: Guiding principles for research involving animals and human beings Am J Physiol Regul Integr Comp Physiol 2002, 283:R281-3.
• [8]Chen Y, Hanaoka M, Droma Y, Chen P, Voelkel NF, Kubo K: Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats. Eur Respir J 2010, 35:904-12.
• [9]Zhang Y, Cao J, Chen Y, Chen P, Peng H, Cai S, et al.: Intraperitoneal injection of cigarette smoke extract induced emphysema, and injury of cardiac and skeletal muscles in BALB/C mice. Exp Lung Res 2013, 39:18-31.
• [10]Yao H, Chung S, Hwang JW, Rajendrasozhan S, Sundar IK, Dean DA, et al.: SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest 2012, 122:2032-45.
• [11]Chen Y, Hanaoka M, Chen P, Droma Y, Voelkel NF, Kubo K: Protective effect of beraprost sodium, a stable prostacyclin analog, in the development of cigarette smoke extract-induced emphysema. Am J Physiol Lung Cell Mol Physiol 2009, 296:L648-56.
• [12]Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonarydisease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-65.
• [13]Wright JL, Cosio M, Churg A: Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2008, 295:L1-15.
• [14]Ochs M: Estimating structural alterations in animal models of lung emphysema. Is there a gold standard? Ann Anat 2014, 196:26-33.
• [15]American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 1995, 152:S77-121.
• [16]Yang Q, Underwood MJ, Hsin MK, Liu XC, He GW: Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development. Curr Drug Metab 2008, 9:661-7.
• [17]He Z, Chen Y, Chen P, Wu G, Cai S: Local inflammation occurs before systemic inflammation in patients with COPD. Respirology 2010, 15:478-84.
• [18]Yao H, Rahman I: Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol 2011, 254:72-85.
• [19]Hillas G, Nikolakopoulou S, Hussain S, Vassilakopoulos T: Antioxidants and mucolytics in COPD management: when (if ever) and in whom? Curr Drug Targets 2013, 14:225-34.
• [20]Yao H, Arunachalam G, Hwang JW, Chung S, Sundar IK, Kinnula VL, et al.: Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM. Proc Natl Acad Sci U S A 2010, 107:15571-6.
• [21]Biffl WL, Moore EE, Moore FA, Barnett CC Jr, Carl VS, Peterson VN: Interleukin-6 delays neutrophil apoptosis. Arch Surg 1996, 131:24-30.
• [22]Yanbaeva DG, Dentener MA, Spruit MA, Houwing-Duistermaat JJ, Kotz D, Passos VL, et al.: IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case–control study. BMC Med Genet 2009, 10:23. BioMed Central Full Text
• [23]Ruwanpura SM, McLeod L, Miller A, Jones J, Bozinovski S, Vlahos R, et al.: Interleukin-6 promotes pulmonary emphysema associated with apoptosis in mice. Am J Respir Cell Mol Biol 2011, 45:720-30.
• [24]Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, et al.: Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:269-78.
• [25]Martin JG, Tamaoka M: Rat models of asthma and chronic obstructive lung disease. Pulm Pharmacol Ther 2006, 19:377-85.
• [26]Brusselle GG, Bracke KR, Maes T, D’hulst AI, Moerloose KB, Joos GF, et al.: Murine models of COPD. Pulm Pharmacol Ther 2006, 19:155-65.
• [27]Plopper CG, Hyde DM: The non-human primate as a model for studying COPD and asthma. Pulm Pharmacol Ther 2008, 21:755-66.
• [28]Chapman RW: Canine models of asthma and COPD. Pulm Pharmacol Ther 2008, 21:731-42.
• [29]Abraham WM: Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm Pharmacol Ther 2008, 21:743-54.
• [30]Mahadeva R, Shapiro SD: Chronic obstructive pulmonary disease * 3: experimental animal models of pulmonary emphysema. Thorax 2002, 57:908-14.
• [31]Wright JL, Churg A: Animal models of cigarette smoke-induced COPD. Chest 2002, 122(6 suppl):S301-6.
• [32]Givi ME, Peck MJ, Boon L, Mortaz E: The role of dendritic cells in the pathogenesis of cigarette smoke-induced emphysema in mice. Eur J Pharmacol 2013, 721:259-66.
• [33]Longhini-Dos-Santos N, Barbosa-de-Oliveira VA, Kozma RH, Faria CA, Stessuk T, Frei F, et al.: Cell therapy with bone marrow mononuclear cells in elastase-induced pulmonary emphysema. Stem Cell Rev 2013, 9:210-8.
• [34]Pera T, Zuidhof AB, Smit M, Menzen MH, Klein T, Flik G, et al.: Arginase inhibition prevents inflammation and remodeling in a guinea pig model of chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2014, 349:229-38.
• [35]Wagner U, Staats P, Fehmann HC, Fischer A, Welte T, Groneberg DA: Analysis of airway secretions in a model of sulfur dioxide induced chronic obstructive pulmonary disease (COPD). J Occup Med Toxicol 2006, 1:12. BioMed Central Full Text
• [36]Misaka S, Sato H, Yamauchi Y, Onoue S, Yamada S: Novel dry powder formulation of ovalbumin for development of COPD-like animal model: physicochemical characterization and biomarker profiling in rats. Eur J Pharm Sci 2009, 37:469-76.
• [37]Tazaki G, Kondo T, Tajiri S, Tsuji C, Shioya S, Tanigaki T: Functional residual capacity and airway resistance in rats of COPD model induced by systemic hyaluronidase. Tokai J Exp Clin Med 2006, 31:125-7.
• [38]Baron RM, Choi AJ, Owen CA, Choi AM: Genetically manipulated mouse models of lung disease: potential and pitfalls. Am J Physiol Lung Cell Mol Physiol 2012, 302:L485-97.
• [39]Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Moore M, Sullivan A, Nicolls MR, et al.: An animal model of autoimmune emphysema. Am J Respir Crit Care Med 2005, 171:734-42.
• [40]Pennisi E: Genomics: sequence tells mouse, human genome secrets. Science 2002, 298:1863-5.
• [41]Jeong YY, Park HJ, Cho YW, Kim EJ, Kim GT, Mun YJ, et al.: Aged red garlic extract reduces cigarette smoke extract-induced cell death in human bronchial smooth muscle cells by increasing intracellular glutathione levels. Phytother Res 2012, 26:18-25.
• [42]Tzortzaki EG, Papi A, Neofytou E, Soulitzis N, Siafakas NM: Immune and genetic mechanisms in COPD: possible targets for therapeutic interventions. Curr Drug Targets 2013, 14:141-8.
• [43]He ZH, Chen P, Chen Y, Zhu YQ, He SD, Ye JR, et al.: Dual effects of cigarette smoke extract on proliferation of endothelial progenitor cells and the protective effect of 5-aza-2’-deoxycytidine on EPCs against the damage caused by CSE. BioMed Res Int 2014, 2014:640752.
• [44]Nana-Sinkam SP, Lee JD, Sotto-Santiago S, Stearman RS, Keith RL, Choudhury Q, et al.: Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med 2007, 175:676-85.
• [45]Taraseviciene-Stewart L, Kraskauskas D, Lee JH, Hanaoka M, Burns N, Parr J, et al.: Cigarette smoke extract (CSE)-induced emphysema in mice. Am J Respir Crit Care Med 2007, 175:A529.
• [46]Yao H, Edirisinghe I, Rajendrasozhan S, Yang SR, Caito S, Adenuga D, et al.: Cigarette smoke-mediated inflammatory and oxidative responses are strain-dependent in mice. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1174-L1186.